

## **CHAIRMAN AND MANAGING DIRECTOR EXERCISE OPTIONS**

**20 December 2021: Rhinomed Limited (ASX:RNO OTCQB:RHNMF)**, a leader in wearable nasal and respiratory technology, is pleased to announce that Chairman Ron Dewhurst and Managing Director Michael Johnson have each exercised 3 million options that were due to expire on 21 December 2021, at an exercise price of \$0.287 per option.

Rhinomed has received exercise notices for the 6 million options with accompanying funds of \$1.722m. The new shares will be issued and rank equally with existing ordinary shares on issue.

The exercise price for the 3 million options exercised by Mr Johnson has been funded by an entity controlled by director and substantial shareholder John McBain. As part of the funding arrangements, Mr Johnson has agreed to sell to Mr McBain 2.7 million shares for the same price as the exercise price. This off-market transaction will occur two days after issue of the shares.

The \$1.722m will contribute to working capital and the company's growth strategy. An Appendix 2A will be released today.

This report has been authorised for release to the market by the Board.

<b>Company</b>	<b>Investor and Media Relations</b>
Michael Johnson, CEO & Director +61 (0) 3 8416 0900 <a href="mailto:mjohnson@rhinomed.global">mjohnson@rhinomed.global</a> Follow us on <b>Twitter</b> @rhinomedceo	Rudi Michelson Monsoon Communications +61(0) 411 402 737 <a href="mailto:rudim@monsoon.com.au">rudim@monsoon.com.au</a>

**About Rhinomed Limited (ASX: RNO, OTCQB:RHNMF)**

Rhinomed Limited is a Melbourne, Australia based ASX listed medical device company that has developed a novel wearable nasal technology platform that can improve air flow and provide both drug delivery and diagnostic capabilities.